dimethyl sulfoxide
Sources réglementaires consultées
Indications approuvées
- Soulagement symptomatique de la cystite interstitielle ; non indiqué dans les infections urinaires bactériennes.
Mises en garde cliniques
- Mise en garde majeure · Il peut libérer de l’histamine et provoquer une hypersensibilité ou une réaction anaphylactoïde ; traiter immédiatement si elle survient. — FDA/DailyMed, set_id 58b25d79-78f2-4953-b0c6-61658dc4ef0d
- Mise en garde majeure · Réaliser un examen ophtalmologique avec lampe à fente avant puis périodiquement, ainsi qu’environ tous les 6 mois une NFS et des tests rénaux/hépatiques. Utiliser avec prudence en cas de tumeur urinaire. — FDA/DailyMed, set_id 58b25d79-78f2-4953-b0c6-61658dc4ef0d
Interactions médicamenteuses
- ModéréeAutres médicaments concomitants
Mécanisme: Le diméthylsulfoxyde peut potentialiser les médicaments concomitants.
Recommandation: Réévaluer tous les médicaments et surveiller une majoration des effets.
FDA/DailyMed, set_id 58b25d79-78f2-4953-b0c6-61658dc4ef0dhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58b25d79-78f2-4953-b0c6-61658dc4ef0d
Effets indésirables
Communs (≥1%)
Goût d’ail · Odeur d’ail de l’haleine ou de la peau · Gêne vésicale transitoire · Cystite chimique transitoire
Rares mais graves
Réaction anaphylactoïde
Grossesse et allaitement
Pendant la grossesse, utiliser uniquement si le bénéfice potentiel justifie le risque fœtal. Utiliser avec prudence pendant l’allaitement car le passage dans le lait est inconnu.
Bibliographie récente (PubMed)
Dimethyl sulfoxide (DMSO) is an amphipathic molecule widely used as a solvent for water-insoluble substances, cryopreserving, and cell-biological therapies. It has known properties as an inducer of cellular differentiation, a free radical scavenger, and a radioprotectant. In addition, DMSO is used for its various therapeutic and pharmaceutical properties, such as anti-inflammatory, local and systemic analgesic, antibacterial, antifungal, antiviral, and membrane penetration enhancement agents. DMSO treatment can be given orally, intravenously, or topically for a wide range of indications. The administration of DMSO exhibits favorable outcomes in human eye diseases with low to none observed ocular or systemic ocular toxicity. Nevertheless, DMSO is an essential and nonpatentable potential therapeutic agent that remains underexplored and ignored by pharmaceutical developers and ophthalmologists. This current review takes data from experimental and clinical studies that have been published to substantiate the potential therapeutic efficacy of DMSO and stimulate the research of its application in clinical ophthalmology. Given that DMSO is inexpensive, safe, and easily formulated into therapeutic medicinal products and conventional ophthalmological drugs, this compound should be further explored and studied in the treatment of a variety of acute and chronic ocular disorders. The concentration of dimethyl sulfoxide (DMSO) has been measured in breastmilk in only one patient after a 15-minute retention in the bladder. The amount in milk is trivial, but its metabolite was not measured and whether it changes the odor or taste of milk was not determined. At most, only about 16% of DMSO in the bladder is absorbed systemically, compared to about 70% after oral administration, so this study does not represent the amount an infant would receive after oral intake by the mother.[1,2]
Dimethyl sulfoxide (DMSO) is a clear, odorless liquid, inexpensively produced as a by-product of the wood pulp industry. DMSO's unique chemical properties allow for its broad applications in a wide variety of cutaneous challenges. Widely available in the USA as a solvent, DMSO is FDA-approved only for the treatment of interstitial cystitis and for use as a preservative for organ transplant. DMSO readily penetrates and diffuses through biological membranes. At low concentrations, DMSO exhibits anti-inflammatory, analgesic, diuretic, vasodilator, anti-platelet aggregation, radio-protective, and muscle-relaxing properties. DMSO is also a vigorous scavenger of hydroxyl free radicals, which may explain its observed beneficial effects on skin rejuvenation and recovery from thermal injury. DMSO has a relatively low level of toxicity. DMSO has shown promise in the off-label treatment of basal cell carcinoma, pressure ulcers, scleroderma, herpes simplex, cutaneous fungal infections, and amyloidosis. The potential of DMSO to serve as an independent or adjuvant topical treatment for these conditions is explored in this review.
Chemotherapy extravasation, the unintended leakage of cytotoxic drugs into surrounding tissues, is a significant complication in oncological treatments, potentially leading to severe tissue damage and long-term consequences. This review explores the factors influencing extravasation risk, including infusion site, patient comorbidities and the physicochemical properties of drugs. Early detection is crucial to prevent irreversible damage. Treatment strategies vary based on the type of drug involved, ranging from topical dimethyl sulfoxide and hyaluronidase to specific antidotes like dexrazoxane for anthracycline extravasations. Preventive measures, including proper catheter placement, drug dilution and patient monitoring, are essential to mitigate risks. Effective management requires a multidisciplinary approach, combining prompt recognition, intervention and ongoing education for healthcare providers to improve patient safety and outcomes in chemotherapy administration. Enhanced training on the early signs of extravasation and advancements in treatment modalities offer critical support in minimizing adverse effects, ensuring timely and appropriate care.
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition marked by chronic pain and voiding dysfunction, often without a clear cause. Management of which often requires a multidisciplinary approach, as well as multiple therapeutic interventions. This review characterizes mechanisms and limitations of currently available treatment modalities for IC/BPS, as well as novel and investigational therapies. Conservative and supportive therapies include cognitive therapies, dietary and fluid management, pelvic floor exercises and bladder training. Additionally, pelvic floor directed therapies such as physical therapy, injections and nerve blocks should be considered. Cystoscopy with hydrodistension is both a diagnostic and therapeutic intervention. Currently available oral therapies include: pentosan polysulfate, amitriptyline, hydroxyzine, silodosin, and non-opioid medications such as cyclobenzaprine. Immunotherapies include cyclosporine and tacrolimus. Available intravesical therapies include dimethyl sulfoxide, lidocaine, oxybutynin, and glycosaminoglycan substitution treatment. Neuromodulation is also available including sacral and pudendal neuromodulation. Finally, we explore emerging therapies and drug delivery systems. In this review, we present currently available treatment options for IC/BPS. These include conservative therapies, oral medications, intravesical therapies, and neuromodulation. Novel and investigational therapies are presented as well as promise for future directions.